The study found:
An 86% reduction in migraine severity in patients with relapsing, remitting MS up to 3.5 years after angioplasty.
A 77% reduction in migraine severity in patients with secondary progressive MS – improvements that lasted for 3.5 years
“The results were loud and clear," said study co-author Clive Beggs, a professor of physiology at Leeds Beckett University in the U.K.

A new study suggests that a highly controversial treatment for multiple sclerosis may in fact reduce headaches in patients with multiple sclerosis and other neurological conditions.